Drug and radiation combo for recurrent pelvic endometrial cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests a combination of two drugs (lenvatinib and pembrolizumab) plus focused radiation to the pelvis for a specific type of endometrial cancer that has returned or cannot be surgically removed. The goal is to see if this treatment is safe and effective for tumors that are pMMR and limited to the pelvic area.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of endometrial cancer that tests as pMMR (proficient mismatch repair).
- Your cancer has come back after surgery or cannot be removed, and it is only in the pelvis or vagina (not spread elsewhere).
- You have not had external radiation to your pelvis, vagina, or abdomen before.
- You are able to perform daily activities with some help (ECOG score 0 to 2).
- Your blood counts and liver, kidney, and heart function are within healthy limits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a chemotherapy combination (carboplatin and paclitaxel) plus the immunotherapy drug pembrolizumab, followed by maintenance pembrolizumab either alone or with a PARP inhibitor called nesuparib. It is for women with advanced or recurrent endometrial cancer that is MMR-proficient (a type where the cells have a normal ability to fix DNA).
This trial tests a combination of two drugs (pembrolizumab and lenvatinib) for endometrial cancer that has come back after initial treatment with chemotherapy and immunotherapy. The study focuses on a specific type of cancer based on genetic testing and may help patients whose cancer didn't respond to standard first-line treatment.
This Phase 3 study tests whether adding a repurposed drug to Keytruda and Lenvima (Len+Pem) helps people with advanced or recurrent endometrial cancer live longer and feel safer. It is designed for tumors that do not have certain immune-system markers (not MSI-H or dMMR).
This Phase 2 trial tests whether a repurposed drug can be safely added to Keytruda and Lenvima for women with advanced or recurrent endometrial cancer. It’s meant to help people who can’t have curative surgery or radiation after prior chemotherapy.
This study tests a new drug (PF-08634404) combined with chemotherapy for women with advanced or recurrent endometrial cancer that is MMR-proficient. The goal is to see if this combination works better than standard care.
This study tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for people with cervical cancer that has come back or spread. The goal is to see if this drug combination can shrink tumors or slow the cancer's growth.
Hear when a new Recurrent Endometrial Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.